HSP90AA1 and breast cancer: Previously, a combination of Hsp90 inhibitor geldanamycin and bortezomib was demonstrated to simultaneously disrupt Hsp90 and proteasome function, promote accumulation of ubiquitinated proteins, and enhance antitumour activity in human breast cancer cells (Mimnaugh et al, 2004, 2006).